Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DARVY LEE MANN

Allopathic & Osteopathic Physicians Pediatrics

NPI
1275832479
CMS profile
1169194
Location
LONGVIEW, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$149.63

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $149.63 9

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DARVY LEE MANN

NPI 1275832479 · CMS profile ID 1169194

Allopathic & Osteopathic Physicians / Pediatrics

LONGVIEW, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275832479?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DARVY LEE MANN, NPI 1275832479, CMS profile ID 1169194. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275832479?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DARVY LEE MANN, NPI 1275832479, CMS profile ID 1169194. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275832479?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DARVY LEE MANN, NPI 1275832479, CMS profile ID 1169194, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1275832479?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $149.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $13.2611/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835901189 CMS
Nestle HealthCare Nutrition Inc. $19.8709/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820925719 CMS
Corium, Inc. $17.6709/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 775552695 CMS
kaleo, Inc. $22.2108/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832122949 CMS
SANOFI PASTEUR INC. $12.9906/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838129265 CMS
kaleo, Inc. $22.1905/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832122947 CMS
Cranial Technologies, Inc $12.2305/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777820105 CMS
Supernus Pharmaceuticals, Inc. $11.7904/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845076605 CMS
SANOFI PASTEUR INC. $17.4204/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838129259 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $150.59 23
PY2020 $67.15 9
PY2021 $149.63 9
PY2022 $300.49 20
PY2023 $408.04 19
PY2024 $226.96 14
PY2025 $385.36 18

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $59,716.71 24
PY2024 Principal investigator $61,020.88 14
PY2023 Principal investigator $72,104.63 22
PY2022 Principal investigator $325,094.46 64
PY2021 Principal investigator $289,713.17 73
PY2020 Principal investigator $296,305.70 95
PY2019 Principal investigator $139,835.21 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $348.31 12/31/2021 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 826484797
Principal investigator 1 Merck Sharp & Dohme Corporation $24,146.48 12/31/2021 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 848741199
Principal investigator 1 Merck Sharp & Dohme Corporation $437.73 12/31/2021 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 848741201
Principal investigator 1 Merck Sharp & Dohme Corporation $46,413.06 12/31/2021 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 848763373
Principal investigator 1 PFIZER INC. $4,562.74 12/23/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832567711
Principal investigator 1 Merck Sharp & Dohme Corporation $13,662.30 12/20/2021 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 848741197
Principal investigator 1 SANOFI PASTEUR INC. $1,373.00 12/17/2021 Non-covered Recipient Entity
Associated Clinicians Of East Texas
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 838375977
Principal investigator 1 GlaxoSmithKline, LLC. $667.94 12/14/2021 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 965538795
Principal investigator 1 GlaxoSmithKline, LLC. $968.52 12/08/2021 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 965538797
Principal investigator 1 PFIZER INC. $4,189.67 12/07/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832566129
Principal investigator 1 GlaxoSmithKline, LLC. $3,129.35 12/02/2021 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS PLLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 965538799
Principal investigator 1 PFIZER INC. $3,718.78 11/24/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832695915
Principal investigator 1 PFIZER INC. $7,878.98 11/23/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832780780
Principal investigator 1 Merck Sharp & Dohme Corporation $12,945.00 11/17/2021 Non-covered Recipient Entity
DCOL CENTER FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants PNEU-PED No dispute reported 06/30/2026 848763367
Principal investigator 1 SANOFI PASTEUR INC. $2,239.00 11/10/2021 Non-covered Recipient Entity
Associated Clinicians Of East Texas
PSK0008 Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine (PCV) when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 838375969
Principal investigator 1 PFIZER INC. $3,584.17 11/05/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832758279
Principal investigator 1 PFIZER INC. $300.00 11/05/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832782663
Principal investigator 1 PFIZER INC. $2,949.83 10/21/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832758289
Principal investigator 1 PFIZER INC. $577.01 10/21/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832768411
Principal investigator 1 PFIZER INC. $98.91 10/09/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832783635
Principal investigator 1 PFIZER INC. $4,908.11 10/08/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832838201
Principal investigator 1 SANOFI PASTEUR INC. $2,239.00 10/06/2021 Non-covered Recipient Entity
Associated Clinicians Of East Texas
PSK0008 Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine (PCV) when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 838375963
Principal investigator 1 PFIZER INC. $5,832.80 09/22/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832733427
Principal investigator 1 PFIZER INC. $1,859.39 09/22/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832848111
Principal investigator 1 PFIZER INC. $802.49 09/21/2021 Non-covered Recipient Entity
DCOL Center for Clinical Rsrch
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832526209
Principal investigator 1 PFIZER INC. $1,417.20 09/20/2021 Non-covered Recipient Entity
DCOL Center for Clinical Rsrch
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832525111
Principal investigator 1 PFIZER INC. $802.49 09/13/2021 Non-covered Recipient Entity
DCOL Center for Clinical Rsrch
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832525265
Principal investigator 1 PFIZER INC. $1,417.20 09/13/2021 Non-covered Recipient Entity
DCOL Center for Clinical Rsrch
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832526019
Principal investigator 1 PFIZER INC. $1,054.11 09/04/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832801259
Principal investigator 1 PFIZER INC. $5,730.20 08/21/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832733045
Principal investigator 1 PFIZER INC. $3,273.14 08/21/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832881953
Principal investigator 1 PFIZER INC. $29,653.70 08/06/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832732941
Principal investigator 1 PFIZER INC. $1,537.90 08/06/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832897829
Principal investigator 1 SANOFI PASTEUR INC. $12,750.00 08/04/2021 Non-covered Recipient Entity
Associated Clinicians Of East Texas PLLC Dcol Center For Clinical Research
PSK0008 Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine (PCV) when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 838358434
Principal investigator 1 PFIZER INC. $4,361.76 07/21/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832829163
Principal investigator 1 PFIZER INC. $3,270.15 07/20/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832883217
Principal investigator 1 PFIZER INC. $10.82 07/06/2021 Non-covered Recipient Entity
DCOL CTR for Clin Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832578425
Principal investigator 1 PFIZER INC. $2,056.73 06/29/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832886143
Principal investigator 1 PFIZER INC. $8,600.26 06/23/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832875023
Principal investigator 1 PFIZER INC. $350.00 06/16/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832714125
Principal investigator 1 PFIZER INC. $2,306.85 06/09/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832793923
Principal investigator 1 PFIZER INC. $350.00 06/05/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832801249
Principal investigator 1 PFIZER INC. $1,500.00 06/05/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832815033
Principal investigator 1 PFIZER INC. $258.90 06/02/2021 Non-covered Recipient Entity
DCOL CTR for Clin Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832920035
Principal investigator 1 PFIZER INC. $802.49 05/26/2021 Non-covered Recipient Entity
DCOL Center for Clinical Rsrch
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832614339
Principal investigator 1 PFIZER INC. $1,417.20 05/26/2021 Non-covered Recipient Entity
DCOL Center for Clinical Rsrch
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832614357
Principal investigator 1 PFIZER INC. $21.64 05/24/2021 Non-covered Recipient Entity
DCOL CTR for Clin Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832776115
Principal investigator 1 PFIZER INC. $2,856.00 05/21/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832772749
Principal investigator 1 PFIZER INC. $4,004.19 05/21/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832826283
Principal investigator 1 PFIZER INC. $10.82 05/10/2021 Non-covered Recipient Entity
DCOL CTR for Clin Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832758159
Principal investigator 1 PFIZER INC. $3,140.87 05/07/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832767491
Principal investigator 1 PFIZER INC. $345.20 04/29/2021 Non-covered Recipient Entity
DCOL CTR for Clin Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832761609
Principal investigator 1 PFIZER INC. $43.28 04/29/2021 Non-covered Recipient Entity
DCOL CTR for Clin Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832775923
Principal investigator 1 PFIZER INC. $3,270.15 04/24/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832837151
Principal investigator 1 PFIZER INC. $2,974.44 04/21/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832874345
Principal investigator 1 PFIZER INC. $1,510.59 04/09/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832768715
Principal investigator 1 PFIZER INC. $200.00 04/09/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832794257
Principal investigator 1 PFIZER INC. $5,764.55 03/24/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832849943
Principal investigator 1 PFIZER INC. $1,942.88 03/24/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832883207
Principal investigator 1 PFIZER INC. $54.10 03/15/2021 Non-covered Recipient Entity
DCOL CTR for Clin Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832729013
Principal investigator 1 PFIZER INC. $431.50 03/15/2021 Non-covered Recipient Entity
DCOL CTR for Clin Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832758167
Principal investigator 1 PFIZER INC. $2,658.52 03/13/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832873465
Principal investigator 1 PFIZER INC. $1,510.59 03/05/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832800325
Principal investigator 1 PFIZER INC. $1,070.32 02/24/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832757327
Principal investigator 1 PFIZER INC. $11,193.07 02/23/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832739289
Principal investigator 1 PFIZER INC. $587.28 02/05/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832840965
Principal investigator 1 PFIZER INC. $1,054.11 02/05/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832901137
Principal investigator 1 PFIZER INC. $1,054.11 01/16/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832847749
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,209.10 01/15/2021 Non-covered Recipient Entity
ASSOCIATED CLINICIANS OF EAST TEXAS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 826492779
Principal investigator 1 PFIZER INC. $1,230.11 01/09/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 832692951
Principal investigator 1 PFIZER INC. $2,433.60 01/09/2021 Non-covered Recipient Entity
Associated Clinicians of East Texas PLLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 832915311
Principal investigator 1 PFIZER INC. $345.20 01/05/2021 Non-covered Recipient Entity
DCOL CTR for Clin Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832909851
Principal investigator 1 PFIZER INC. $43.28 01/05/2021 Non-covered Recipient Entity
DCOL CTR for Clin Research
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS No dispute reported 06/30/2026 832922455